Objective: Prevalence of end-stage renal disease, modality of treatment, and type of hemodialysis vascular access used varies widely by race/ethnicity in the United States, but outcomes of hemodialysis vascular access by race/ethnicity are poorly described. The objective of this study is to evaluate variations in outcomes of hemodialysis vascular access in the elderly by race/ethnicity.
The prevalence of end-stage renal disease (ESRD) in the United States is higher in all non-White racial groups compared with Whites. 1 In 2013, the prevalence per million among Blacks was higher than any other racial group at 5584 compared with 2196 among Asians, 2133 among Native Americans, 2970 among Hispanics, and 1499 among Whites. 1 Additionally, among patients with prevalent ESRD, the percentage of Blacks that use hemodialysis as their treatment modality is the highest, at 76%, compared with 59% of Whites, 70% of Native Americans, 61% of Asians, and 69% of Hispanics. 1 Furthermore, the type of vascular access used varies significantly by race/ethnicity. Among hemodialysis patients in 2013, 64.3% of Whites were using an arteriovenous fistula for vascular access, compared with 56.9% of Blacks, 67.2% of Asians, and 67.5% of Hispanics. 1 Despite the recognition that these racial/ethnic disparities exist, little work has been done to examine the outcomes of vascular access type by race/ethnicity. Outcomes of hemodialysis vascular access are particularly relevant in the elderly given the 31% per year all-cause mortality in the age 65þ years hemodialysis population. 1 National guidelines, initiatives, and the recently instituted Center for Medicare and Medicaid Services ESRD Quality Incentive Program all place increasing emphasis on prioritizing the creation of fistulas over grafts for hemodialysis vascular access. 2, 3 However, there is increasing evidence that fistula maturation and patency may be worse in elderly compared with younger patients with ESRD. [4] [5] [6] The combination of elevated 1-year mortality rates in elderly patients with ESRD and lower fistula maturation/patency suggests that a significant proportion of elderly hemodialysis patients may not survive to experience the purported long-term benefits that fistulas provide vs grafts, making the short-term results of fistula/graft creation for hemodialysis vascular access an important area of investigation.
The purpose of this study is to determine the variations in 12-month outcomes of fistula vs graft creation among non-White race/ethnicity groups compared with Whites in dialysis-dependent patients undergoing first time fistula/graft creation in the Medicare population.
METHODS
Medicare outpatient, inpatient, and carrier files from 2006 through 2011 were queried for upper extremity vascular access procedures identified by the Current Procedural Terminology (CPT) codes for fistula and graft (Supplementary Table I , online only). Index fistula/graft creation was defined as the first occurrence of the CPT code per beneficiary during the study period. Repeat fistula/graft creation was defined as any new fistula/graft creation, identified by CPT code, performed in the 12 months subsequent to index fistula/graft, regardless of whether the index procedure was a fistula or a graft. Tunneled hemodialysis catheter placement procedures were identified by CPT code (Supplementary Table I , online only).
Inclusion criteria were age $66 years and dialysis dependent at time of index fistula/graft creation, qualification for Medicare exclusively by virtue of age, complete demographic and comorbidity data, and continuous enrollment in fee-for-service Medicare for 12 months before and after index fistula/graft creation. By excluding patients who qualified for Medicare by virtue of ESRD and limiting the patient population to those who were enrolled in Medicare for 12 months before index fistula/ graft creation, we limit the cohort to patients who were undergoing first time dialysis vascular access creation to the best of our ability. Patients who died within 12 months after index fistula/graft creation were included. Comorbidities were defined by having ever met the claims criteria of the Chronic Condition Data Warehouse as of the date of index fistula/graft creation. 7 Dialysis dependence was identified using BerensonEggers Type of Service (BETOS) Codes P9A (Dialysis Services Medicare Fee Schedule) and P9B (Dialysis Services Non-Medicare Fee Schedule). BETOS codes are assigned for each Healthcare Financing Administration Common Procedure Coding System procedure code. Each Healthcare Financing Administration Common Procedure Coding System code is assigned to a single BETOS code. BETOS code categories are designed to permit objective assignment and be stable over time. 8 Chronic dialysis dependence was defined as at least one occurrence of BETOS 9A or 9B during the 12 months preceding index fistula/graft month or within 30 days after creation of index fistula/graft.
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In Medicare claims data, beneficiary race is determined by taking the beneficiary race code that has historically been used by the Social Security Administration and applying an algorithm developed by the Research Triangle Institute (RTI). The RTI algorithm incorporates beneficiary language preference, the language that the beneficiary has requested that the Social Security Administration use when sending notices, the source of the beneficiary's Medicare enrollment database race/ ethnicity code, the state in which the beneficiary resides, and the first and last name of the beneficiary. The RTI algorithm has been shown to significantly improve the accuracy of coding for Hispanics and Asians or Pacific Islanders. 10 The race categories designated by Medicare claims data are non-Hispanic White, (hereafter referred to as White), Black, Asian/Pacific Islander (hereafter referred to as Asian), Hispanic, American Indian/Alaska Native, and Other. Outcomes were adjusted for using three increasingly comprehensive models. Model 1 covariates were age and its square, sex, index year, index month, total covered charges from outpatient, inpatient, and carrier files in the year preceding index fistula/graft creation date, inpatient setting for the index fistula/graft creation, and all comorbidities available from the Chronic Condition Data Warehouse, (except chronic kidney disease which was used to select the cohort). In model 2, community contextual factors (obtained by linking residential zip code from Medicare enrollment files to the 2000 Census) were included in addition to all covariates in model 1. 11,12 In model 3, binary indicator variables for hospital referral region were included in addition to all covariates in model 2. Hospital referral regions represent regional healthcare markets and are included in an effort to control for regional variation in access to Statistical analysis was conducted using Stata v 13.1 (StataCorp, College Station, Texas). Two group comparisons for age were assessed by a t-test of equality of means. Two group comparisons for dichotomous outcomes were assessed by c 2 tests. Prevalence of access procedure type was analyzed by race/ethnicity groups using logistic regression, controlling for the factors described in the various models. Logistic regressions of early failure were performed based on index fistula vs graft, controlling for the factors described in the various models. Adjusted outcomes were calculated based on predictions, which varied the access procedure for each patient while holding all other covariates fixed, averaged across the sample. 14 The primary outcome measures of this study were early failure and 12-month failure free survival, specifically, the variations in the difference between fistula and graft of these two outcomes among race/ethnicity groups. Early failure was defined by creation of another fistula/graft and/or tunneled hemodialysis catheter placement in the 12 months following index fistula/graft. Calculations of incidence of early failure include patients who expired during the 12 months following index fistula/graft procedure in the denominator. Twelve-month failure-free survival was defined by the patient surviving for 12 months after index fistula/graft creation without occurrence of another fistula/graft creation or tunneled catheter placement. Survival analysis was performed. 15 To account for multiple comparisons, a Bonferroni correction can be applied to the P value for our two primary outcomes, the variation of the difference in fistula and graft for non-White vs White for early failure, and 12-month failure-free survival. For each primary outcome, there were three hypotheses for equality of Black, Asian/ Pacific Islander, and Hispanic, respectively, with Whites. This results in a total of six hypotheses. After applying a Bonferroni correction, the required P value for statistical significance on each hypothesis is lowered from .05 to .008. As the Bonferroni correction can be a conservative approach, both the corrected and uncorrected significance are presented.
ARTICLE HIGHLIGHTS
This research was deemed exempt from review by the Institutional Review Board as the study was retrospective, the Medicare data used was deidentified, and there was no contact with human subjects for this research. Patient informed consent was unnecessary for this study as only deidentified data was used, and there was no contact with human subjects.
RESULTS
During the study period, 16,402 index fistula and graft creations met the inclusion criteria; 10,507 (64.1%) procedures were performed in Whites, 3331 (20.3%) in Blacks, 685 (4.2%) in Asians, 1570 (9.6%) in Hispanics, 146 (0.89%) in American Indians/Alaska Natives, and 163 (0.99%) in Other. The small sample size of American Indians/Alaska Natives and Other would preclude meaningful statistical analysis, and the results of both groups are not further presented.
Patient demographics, comorbidities, and zip code community contextual factors varied by graft vs fistula and across racial/ethnic groups (Table I; Supplementary  Table II , online only). The mean age of patients who underwent graft was slightly older than patients who underwent fistula in all race/ethnicity groups, and a smaller proportion of female patients underwent fistula. Patients who underwent graft had higher mean total covered billed charges in the 12 months before the fistula/graft creation date in all race/ethnicity groups. There was a trend toward a higher incidence of comorbidities in the graft group compared with the fistula group across race/ethnicity groups. In most cases across race/ ethnicity groups, when there was a difference in zip code community contextual factors between the fistula and graft group, the graft group was more likely to be associated with disadvantaged community contextual factors.
Unadjusted, fistulas accounted for 79.9% of the vascular access procedures performed in Whites. A smaller proportion of procedures performed in Blacks, Asians, and Hispanics were fistulas (Table II) . The intermediate models did not result in major changes in absolute or relative proportions of fistulas except in Hispanics (Supplementary Table III , online only). Upon adjusting for the variables in model 2, the difference in proportion of fistulas performed in Hispanics vs Whites became negligible. After further adjusting for hospital referral region (model 3), 78.0% of the index vascular access procedures performed in Whites were fistulas. Compared with Whites, a smaller proportion of the index procedures performed in Blacks and in Asians were fistulas (Table II) . There was no difference between the proportion of index fistulas performed in Whites vs Hispanics.
Overall, 4707 (28.7%) patients expired during the 12 months postindex vascular access procedure. The unadjusted 12-month mortality rates were White 31.3%, Black 25.0%, Asian 23.3%, and Hispanic 23.3%. The unadjusted 12-month mortality rate was higher in grafts compared with fistulas for Whites and Blacks, with no difference for Asians or Hispanics (Table III) . Upon adjusting for demographics and comorbidities, the difference in mortality between graft and fistula became no longer significant for Blacks. This pattern persisted with further adjustment for community contextual factors and hospital referral region. In the fully adjusted model, the mortality in grafts was higher than fistulas for Whites (32.4% vs 30.0%; P ¼ .03; Table III ). In Blacks, Asians, and Hispanics, the mortality in the there was no difference between the mortality in the grafts and the fistulas. The difference in Supplementary Table II  (online only) .001 Supplementary Table II  (online only) .009 Supplementary Table II  (online only) .23
Supplementary mortality between grafts and fistulas within Blacks, Asians, and Hispanics was not significantly larger or smaller than the difference between procedures for Whites in any of the models (Table III) . In all race/ethnicity groups, the unadjusted incidence of early failure (repeat fistula or graft, or tunneled catheter placement) was lower in patients who underwent graft than fistula (Table IV) . The intermediate models did not result in major changes in the absolute or relative incidence of early failure (Supplementary Table IV , online only). After adjustment for all covariates (model 3), the incidence of early failure was lower after graft than fistula in all race/ethnicity categories (Table IV) . In Whites, the incidence of early failure was 34.9% for graft vs 43.5% for fistula (P < .001), resulting in an incidence of early failure in Whites that was 8.6% lower after graft vs fistula (Table IV) . In Blacks, grafts had a 16.2% lower incidence of early failure than fistulas, significantly larger than the 8.6% difference in Whites (P < .001; Table IV ). In Asians and Hispanics, the difference in early failure of graft vs fistula was not significantly larger or smaller compared with Whites.
In Whites, Blacks, and Hispanics, the unadjusted 12-month failure-free survival rate was significantly higher for grafts than for fistulas (Table IV) . The intermediate models did not result in major changes in the absolute or relative 12-month failure-free survival (Supplementary  Table IV , online only). In Whites, Blacks, and Hispanics, the fully adjusted 12-month failure-free survival was higher after graft vs fistula (Table IV) . In Asians, there was no difference in 12-month failure-free survival for graft vs fistula. In Whites, the 12-month failure-free survival was 41.9% for graft compared with 38.9% for fistula (P ¼ .008 ; Table IV) . Restated, the 12-month failure-free survival in Whites was 3.0% higher for grafts compared with fistulas. In Blacks, the 12-month failurefree survival was 11.2% higher for grafts compared with fistulas, significantly larger than the 3.0% difference Predictive margin adjusted for age and its square, sex, index year, index month, total covered charges from outpatient, inpatient, and carrier files in the year preceding index fistula/graft creation date, inpatient setting for the index fistula/graft creation, and all comorbidities available from the Chronic Condition Data Warehouse (except chronic kidney disease), community contextual factors, and hospital referral region. seen in Whites (P < .001; Table IV ). In Hispanics, the 12-month failure-free survival was 9.7% higher for grafts compared with fistulas, which is also larger than the difference seen in Whites (P ¼ .02; Table IV ). However, upon applying the Bonferroni correction, this P value becomes no longer statistically significant. In Asians, the difference in 12-month failure-free survival of graft vs fistula was not significantly larger or smaller compared with Whites.
DISCUSSION
It is well-documented that the prevalence of ESRD in the United States varies widely by race/ethnicity. 1 Although the modality of ESRD treatment varies by race/ethnicity, hemodialysis is still the most prevalent mode of renal replacement therapy used by all race/ ethnicity groups. 1 It is also well-documented that the prevalence of hemodialysis vascular access type varies widely by race/ethnicity. 1 In the face of such disparities in care, a well-known Institute of Medicine report "Confronting Racial and Ethnic Disparities in Health Care" called for further research to better understand how race and ethnicity are associated with disparities in outcomes from care. 16 Despite this, little work has been done to examine the outcomes of hemodialysis vascular access by race/ethnicity. Among prevalent hemodialysis patients in 2013, 64.3% of Whites were using a fistula for vascular access, compared with 56.9% of Blacks, 1 a difference that is reflected in our study where there was a 12% higher fully adjusted incidence of fistula creation in Whites compared with Blacks. This could suggest that there is something inherently related to being Black that makes a patient less likely to undergo fistula creation compared with a White patient. There is some evidence to indicate that Blacks have smaller diameter upper extremity veins than non-Black patients, which may contribute to Blacks a P value for difference in incidence of early failure for fistula vs graft within race/ethnicity group compared with difference in incidence of early failure for fistula vs graft within Whites. b Predictive margin adjusted for age and its square, sex, index year, index month, total covered charges from outpatient, inpatient, and carrier files in the year preceding index fistula/graft creation date, inpatient setting for the index fistula/graft creation, and all comorbidities available from the Chronic Condition Data Warehouse (except chronic kidney disease), community contextual factors and hospital referral region. c P value for difference 12-month failure-free survival for fistula vs graft within race/ethnicity group compared with difference 12-month failure-free survival for fistula vs graft within Whites. d After applying the Bonferroni correction, this value becomes no longer statistically significant.
having a lower prevalence of fistula creation, a trend that has been reported by numerous studies. [17] [18] [19] However, the reported data regarding racial/ethnic variations in upper extremity vein diameter is very limited. Our study also found that Asians had a significantly lower incidence of fistula creation compared with Whites. However, United States Renal Data System (USRDS) data demonstrates a slightly higher prevalence of Asians compared with Whites using a fistula for vascular access (67.2% vs 64.3%), although USRDS does not report whether this difference is significant. 1 It is possible that this difference in fistula use and fistula creation is attributed to a higher incidence of fistula creation in younger Asians, a group not included in our study. In addition, we found that there was no difference in the fully adjusted incidence of fistula created between Hispanics and Whites. Interestingly, the unadjusted model demonstrated a significantly lower incidence of fistula creation in Hispanics vs Whites. However, once community contextual factors were adjusted for, this difference was reduced to 1% and became nonsignificant, suggesting that the unadjusted difference is related to community characteristics of where the Hispanic patients live, and not to being Hispanic itself. The overall mortality in our study is consistent with the USRDS reported all-cause mortality of 31% per year in the elderly population with ESRD. 1 The unadjusted mortality rate in Whites was higher than all other race/ethnicity groups. This has been demonstrated in numerous previous reports documenting increased mortality risk among White patients with ESRD, which cannot be explained by differences in comorbidities or transplantation rates, or vascular access type. 18, 20, 21 Within Whites, after full adjustment, grafts were associated with a 2.4% higher mortality than fistulas. Although this difference in mortality is statistically significant, its magnitude is so small that may not be considered clinically significant. Similarly, other authors have demonstrated in a decision and cost-utility analysis that fistula use was associated with a minimal improvement in survival over grafts of only 2.6 months. 22 Whites were the only race/ethnicity group in our study that experienced a lower mortality with fistula compared with graft, further calling into question the purported mortality benefit of fistula over graft. Within all race/ethnicity groups, the incidence of early failure was significantly lower after index graft vs fistula creation, consistent with the growing body of literature indicating that fistula maturation failure is high in the elderly. 4, 5 The fully adjusted difference between graft and fistula for Blacks was nearly twice that of Whites and highly statistically significant. In the unadjusted model, the difference was even larger, becoming smaller with each model, suggesting that variations in demographics, comorbidities, community contextual factors, and hospital referral region account for a portion of this difference in early failure between Blacks and Whites. The remaining difference is unexplained by the factors included in model 3, suggesting that another factor associated with being Black causes the significantly larger difference between graft and fistula early failure compared with Whites. The rate of early fistula thrombosis and failure to mature in Blacks has been demonstrated to be as high as 45%, consistent with our findings. 23 In addition, Black race has been shown to be an independent risk factor for hospitalization because of vascular access-related morbidity. 24 Despite Blacks being the highest users of hemodialysis and having nearly twice the prevalence of ESRD compared with any other racial/ethnic group, the underlying causes of these poor vascular access outcomes have not been well studied. A study published in 2002 demonstrated that Lipoprotein (a), a low density lipoprotein associated with increased risk of atherothrombosis, is present in higher in Blacks compared with Whites. 25 Blacks with the highest lipoprotein (a) levels had a higher incidence of requiring vascular access interventions; there was no association among Whites.
Further studies do not appear to have been performed. The optimal outcome for any patient with ESRD, after vascular access creation, is to survive without requiring another vascular access creation or tunneled catheter placement, measured in our study by failure-free survival at 12 months. Overall, the 12-month failure-free survival was sobering for all groups with a fully adjusted high of only 51.9% in Hispanics who underwent grafts. Given the poor life expectancy of elderly patients with ESRD, it is even more important that quality of life issues associated with failed vascular access procedures be taken into consideration when determining the optimal access type for each individual patient. Among Whites, there was no significant difference in unadjusted failure-free survival between grafts and fistulas, with fistulas even having a slight 1.1% absolute advantage over grafts. Upon adjusting for demographics and comorbidities, grafts conferred a failure-free survival advantage over fistula, suggesting that the unadjusted equipoise between fistula and graft failure-free survival for Whites is attributed to variations in demographics and comorbidities. The failure-free survival advantage of grafts increased slightly with each successive model, to only a high of 3%.
Within Hispanics, the fully adjusted failure-free survival was greater after grafts vs fistulas with a difference of nearly 10%, a larger difference compared with Whites, which may or may not be statistically significant. Among Asians, the fully adjusted failure-free survival after graft was over 6% higher than fistula; however, this did not achieve statistical significance, possibly because of small sample size. The difference in failure-free survival between fistula and graft was greatest among Blacks. The fully adjusted advantage of grafts over fistulas Blacks was nearly four times that seen in Whites. Again, this suggests that there is a significant variation in outcomes of vascular access in the elderly among race/ethnicity groups and that particularly in Blacks and Hispanics, grafts may confer improved outcomes compared with fistulas.
This study has a number of limitations; the most significant being that it is an observational study. Although we controlled for all readily available confounders measured in claims data, it is possible that worse outcomes in certain minority populations compared with Whites can be attributed to factors other than race/ethnicity. In fact, we believe that future studies should explore these variations in outcomes by race/ethnicity to determine with greater granularity the contributing factors and whether the factors are modifiable. The RTI algorithm used by Medicare claims does not recognize Hispanic as an ethnicity and does not allow for the fact that it is possible to be Hispanic as well as White or Black or any other race. Although we acknowledge this important distinction, we are limited by the categories that Medicare claims records. Other access-related complications, such as infection and revision, were not included in this study because of the fact that the CPT codes for these complications are not as clear as codes for fistula/graft creation. As a result, the total incidence of encounters related to vascular access is likely to be significantly underestimated. In addition, we did not measure the number of catheter-dependent days, which may vary significantly by fistula vs graft and would be an important outcome to examine in future studies.
CONCLUSIONS
Outcomes of grafts vs fistulas in the elderly vary significantly by race/ethnicity and are not accounted for by the demographics, comorbidities, community contextual factors, or hospital referral region studied. The decreased risk of early failure after graft vs fistula creation is larger in Blacks compared with Whites. The higher failure-free survival at 12 months after graft vs fistula creation is larger in Blacks compared with Whites and trends toward being larger in Hispanics compared with Whites. It is imperative that vascular access guidelines be updated to take into consideration individual patient characteristics, including age, race/ethnicity, and life expectancy and that future research focus on identifying potentially modifiable risk factors for these variations in outcomes. a Adjusted for age and its square, sex, index year, index month, total covered charges from outpatient, inpatient, and carrier files in the year preceding index fistula/graft creation date, inpatient setting for the index fistula/graft creation, and all comorbidities available from the Chronic Condition Data Warehouse (except chronic kidney disease). b Adjusted for age and its square, sex, index year, index month, total covered charges from outpatient, inpatient, and carrier files in the year preceding index fistula/graft creation date, inpatient setting for the index fistula/graft creation, all comorbidities available from the Chronic Condition Data Warehouse (except chronic kidney disease) and community contextual factors. c Predictive margin for prevalence of fistula created vs graft.
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